L26/P-261 Multicenter validation of artificial zona pellucida removal at the pronuclear stage: Enhancing blastocyst developmental potential in refractory infertility without compromising neonatal outcomes
Human Reproduction · 01.07.2026 · 41 (Supplement_1)
DOI: 10.1093/humrep/deag083.597 ↗Kurz gefasst
Fachartikel in der Zeitschrift Human Reproduction, online erschienen am 08.07.2026. Verfasst von K. Yumoto und 9 weiteren Autor:innen.
Abstract (Originalsprache)
Study question Does pronuclear-stage artificial zona pellucida removal (ZP-free) improve embryonic development for refractory infertility with poor-cleavage background, and is this benefit reproducible across different culture environments? Summary answer ZP-free method significantly improves all stages of embryonic development across diverse culture environments, providing an effective clinical strategy for refractory infertility patients with poor-cleavage background. What is known already Previous research established that ZP-free method effectively suppresses blastomere fragmentation during the early cleavage stages in patients with refractory infertility (Yumoto et al., Fertil Steril Rep, 2024). Single-center pilot data indicated significant improvements in good-quality early cleavage embryos, blastulation, morphologically good-quality blastocyst development, and cryopreservation significantly increased in the ZP-free embryos. However, the clinical robustness and reproducibility of this technique across diverse laboratory settings remain unverified. The present study evaluates the efficacy of the ZP-free method across four distinct facilities to validate its reproducibility and clinical benefit as an intervention for patients with recurrent poor embryonic development. Study design, size, duration This is a multi-center retrospective study that was conducted in four different assisted reproductive technology (ART) clinics between January 2022 and December 2025. We analyzed 115 patients (187 cycles) with a history of recurrent poor early cleavage. A total of 926 normally fertilized oocytes (2PN zygotes) were randomly allocated into two groups: the ZP-free (n = 464) and the ZP-intact (embryos with the ZP present; n = 462). Participants/materials, setting, methods Two PN zygotes were placed into hypertonic solution to induce slight contractions of the ooplasm in order to evaluate the grade of ooplasm/ZP-adhesion. Subsequently, for ZP-free embryos the ZP was partially opened via laser, and the ooplasm was completely separated using the medium-blowing method. Both ZP-intact and ZP-free embryos were cultured in time-lapse monitoring systems for up to seven days. Developmental parameters, clinical pregnancy rates (CPR) following frozen-thawed embryo-transfer (FET), and neonatal outcomes were compared. Main results and the role of chance The mean patient age was 38.8±4.4 years. The ZP-free group showed significantly higher rates compared to the ZP-intact group in: good-quality early cleavage (fragmentation <20%) (25.4% vs. 12.6%, P<0.01), blastocyst development (49.3% vs. 35.9%, P < 0.01), and high-quality blastocyst formation (22.6% vs. 16.2%, P<0.05). The effective utilization rate was also significantly higher in the ZP-free compared to the ZP-intact group (30.6% vs. 24.9%, respectively; P<0.05). Regarding clinical outcomes (75 patients, 119 FET cycles), no statistically significant differences were observed between ZP-free (n = 62) and ZP-intact (n = 57) groups in CPR (23.3% vs. 23.2%, respectively) or miscarriage rate (28.6% vs. 30.8%, respectively). Furthermore, neonatal parameters for live births, including mean gestational age (39.4 vs. 39.5 weeks), birth height (49.5 cm vs. 48.2 cm), and birth weight (3198.1 g vs. 3058.2 g), showed no significant differences. Collectively, these findings demonstrate that the ZP-free method significantly optimizes embryonic development and utilization rates without compromising clinical safety or neonatal health. Furthermore, the consistency of these outcomes across four independent facilities underscores the technical reproducibility and clinical robustness of the procedure across diverse ART laboratory settings. Limitations, reasons for caution The retrospective nature of the study and the limited sample size for neonatal data are primary limitations. While improved blastocyst rates were consistent across multiple centers, further prospective randomized controlled trials are warranted to confirm the long-term safety and absolute efficacy of pronuclear-stage artificial ZP removal. Wider implications of the findings ZP-free method significantly improves embryo development in patients with repeated early cleavage failure, due to excessive fragmentation. By mitigating ZP-related constraints, this technique offers a promising clinical strategy for refractory infertility cases, potentially increasing the number of transferable blastocysts and improving cumulative success rates in challenging ART cycles. Trial registration number No
Zitieren
APA
Yumoto, K., Tsounapi, P., Harada, Y., Hirata, R., Kanno, H., Ozaki, T., Yoshida, H., Habara, T., Kinutani, M., & Mio, Y. (2026). L26/P-261 Multicenter validation of artificial zona pellucida removal at the pronuclear stage: Enhancing blastocyst developmental potential in refractory infertility without compromising neonatal outcomes. Human Reproduction, 41(Supplement_1). https://doi.org/10.1093/humrep/deag083.597
Vancouver
Yumoto K, Tsounapi P, Harada Y, Hirata R, Kanno H, Ozaki T, et al. L26/P-261 Multicenter validation of artificial zona pellucida removal at the pronuclear stage: Enhancing blastocyst developmental potential in refractory infertility without compromising neonatal outcomes. Human Reproduction. 2026;41(Supplement_1). doi:10.1093/humrep/deag083.597
BibTeX
@article{Yumoto2026,
author = {Yumoto, K. and Tsounapi, P. and Harada, Y. and Hirata, R. and Kanno, H. and Ozaki, T. and Yoshida, H. and Habara, T. and Kinutani, M. and Mio, Y.},
title = {L26/P-261 Multicenter validation of artificial zona pellucida removal at the pronuclear stage: Enhancing blastocyst developmental potential in refractory infertility without compromising neonatal outcomes},
journal = {Human Reproduction},
year = {2026},
volume = {41},
number = {Supplement_1},
doi = {10.1093/humrep/deag083.597}
}
EUVIMED